What biomarkers are important for prostate cancer prognosis

Understanding biomarkers is an important part of assessing prostate cancer. Biomarkers are measurable indicators in your body that can provide information about your health, including the presence, characteristics, and likely behavior (prognosis) of cancer. For prostate cancer, doctors use a combination of standard clinical factors and various biomarker tests to understand the disease and guide treatment decisions.

Standard Medical Guidance

According to the NCCN Guidelines for Patients: Early-Stage Prostate Cancer, oncologists use several tools to assess the risk of prostate cancer getting worse and to predict its likely course (prognosis). These tools help determine whether immediate treatment is needed and what type of treatment might be most effective.

How Doctors Think (Clinical Reasoning): Oncologists typically consider a comprehensive set of factors to assess prostate cancer risk and prognosis. This involves looking at the clinical characteristics of the cancer, such as PSA levels, biopsy results, and tumor stage, and combining this with information from specialized tests, including molecular biomarker tests. This multi-faceted approach helps to create a more accurate picture of an individual's cancer.

Key Biomarkers and Assessment Tools:

1. Prostate-Specific Antigen (PSA) Level:

   • The PSA test is a blood test that measures the amount of PSA, a protein made by the prostate gland, in your bloodstream. While a high PSA level can be a sign of prostate cancer, it doesn't automatically mean cancer is present, as other factors like age, race, an enlarged prostate, or certain activities can also affect PSA levels. However, an unusually high or rising PSA can be a warning sign that may prompt further testing [NCCN Guideline 11, 14].
   • PSA Density: For patients with a larger prostate, PSA density (PSA level divided by prostate size) can be calculated to adjust for prostate size, as a higher PSA density (e.g., above 0.15 ng/mL²) may indicate a greater likelihood of cancer [NCCN Guideline 14].

2. Biopsy Results:

   • A biopsy is the main way to confirm cancer and provides crucial information. A pathologist examines tissue samples under a microscope to determine if cancer cells are present, how many core samples contain cancer, and the percentage of cancer in each core. This helps estimate the amount and location of cancer in the prostate [NCCN Guideline 5].
   • Grade Group (Gleason Score): The pathologist assigns a Grade Group (based on the Gleason score) which describes how aggressive the cancer cells look under the microscope. This is a key factor in risk assessment and prognosis [NCCN Guideline 6, 8, 13].

3. Tumor Stage (TNM System):

   • Staging describes the severity of the cancer and how far it has spread. The TNM (Tumor, Node, Metastasis) system is used, where 'T' describes the primary tumor, 'N' indicates if cancer has spread to lymph nodes, and 'M' indicates if it has spread to distant parts of the body. The scores are combined to assign a stage, which is critical for predicting the disease course and planning treatment [NCCN Guideline 8, 12, 18].

4. Risk Groups:

   • Your care team combines your PSA level, Grade Group, tumor stage, and biopsy results to classify your disease into one of five risk groups (from very low to very high risk). Your risk group is the basis for your prognosis and guides treatment options; lower-risk patients may receive minimal or no immediate treatment, while higher-risk patients usually receive more aggressive treatment [NCCN Guideline 6, 8, 13].

5. Nomograms:

   • A nomogram is a mathematical tool that predicts your prognosis by comparing your cancer characteristics (age, PSA, Gleason score, etc.) to data from thousands of other patients. Nomograms can provide more accurate estimates of cancer risk than risk groups alone and are used alongside other tools to plan treatment [NCCN Guideline 1, 17].

6. Molecular Biomarker Tests:

   • These tests use samples of your blood or prostate/lymph node tissue to look for specific molecules released by a tumor. They are also known as molecular tumor tests, genomic tests, somatic tests, or tumor profiling. Examples for prostate cancer include Decipher, Genomic Prostate Score, and Prolaris. These tests can help identify patients with lower-risk prostate cancer who may not need immediate treatment, potentially sparing them from aggressive treatments and their side effects [NCCN Guideline 1, 4, 20].
   • Genetic Tests: These tests look for abnormal changes (mutations) in your genes.
     • Germline Testing: This looks for inherited mutations (passed down in families) that can increase cancer risk. It's often suggested if you have a family history of cancer [NCCN Guideline 5, 20].
     • Molecular Biomarker Testing (Somatic Testing): This looks for mutations that occur spontaneously in the tumor cells themselves. This information can help choose a treatment plan, especially by identifying specific abnormalities in DNA repair genes (like BRCA1, BRCA2, ATM, PALB2, FANCA) that may respond to targeted therapies like PARP inhibitors [NCCN Guideline